EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Efficacy and safety of tumour necrosis factor inhibitors in unexplained recurrent spontaneous abortion: A systematic review and meta-analysis

Xuan Gu, Chao Zhou, Hexiang Qiu, Yifan Bao, Yuanyuan He, Jing Zhu, Jun Yue, Yan Wang, Yicun Man, Yue Zhuang, Yong Yang, Yue Wu

Journal of Reproductive Immunology · 2026

DOI: 10.1016/j.jri.2026.104956 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Reproductive Immunology, 2026. Verfasst von Xuan Gu und 11 weiteren Autor:innen. Beteiligte Einrichtung: 3201 Hospital, Hanzhong, Shaanxi 723000, China; Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy…. Hauptthemen laut MEDLINE: Abortion, Habitual, Tumor Necrosis Factor-alpha, Tumor Necrosis Factor Inhibitors. Die Arbeit nennt 57 Literaturangaben. Gefördert von: Sichuan Provincial Science and Technology Support Program, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Whether tumour necrosis factor inhibitors (TNFi) provide a safe and effective adjunctive therapy for enhancing pregnancy outcomes in women with unexplained recurrent spontaneous abortion (URSA) remains unclear. To resolve this ambiguity, we performed a meta-analysis. We systematically searched Web of Science, PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure (CNKI), and Wanfang Database (last search was performed on January 8, 2026). Eligible studies included randomized controlled trials (RCTs) and retrospective cohort studies (RCS) assessing TNFi in URSA patients. A random-effects model was applied. Odds ratios (ORs) or mean differences (MDs) with 95% confidence intervals (CIs) were calculated. A total of 529 patients from four studies were included. The results showed that adjunctive TNFi therapy significantly improved the live birth rate (OR = 2.50, 95% CI: 1.66-3.78; P < 0.0001) and reduced the miscarriage rate (OR = 0.37, 95% CI: 0.24-0.59; P < 0.0001). TNFi was associated with a slightly higher neonatal Apgar score without increasing the risk of adverse maternal or other neonatal outcomes. Exploratory subgroup analysis suggested that the benefit of TNFi on live birth rates appeared consistent regardless of concomitant intravenous immunoglobulin (IVIG) use; however, this finding requires further validation. Adding TNFi to conventional treatment may represent a promising strategy to improve live birth rates in women with URSA, with no major safety concerns identified. Nevertheless, the small number of included studies provides insufficient evidence for definitive conclusions and precludes a robust assessment of publication bias, thereby compromising the reliability of our findings. (PROSPERO: CRD420261305573).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Abortion, HabitualTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsHumansFemalePregnancyPregnancy OutcomeLive BirthTreatment OutcomeRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Live birth rateMeta-analysisSystematic reviewTumour necrosis factor inhibitorUnexplained recurrent spontaneous abortion

Substanzen

Tumor Necrosis Factor-alphaTumor Necrosis Factor Inhibitors

Autor:innen und Institutionen

  • 3201 Hospital, Hanzhong, Shaanxi 723000, China; Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of…
  • Department of Gastroenterology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, China.
  • School of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, China.
  • Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and…
  • Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, China.
  • Department of Gynaecology and Obstetrics, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, China.

Förderung

  • Sichuan Provincial Science and Technology Support Program
  • National Natural Science Foundation of China

Zitieren

APA

Gu, X., Zhou, C., Qiu, H., Bao, Y., He, Y., Zhu, J., Yue, J., Wang, Y., Man, Y., Zhuang, Y., Yang, Y., & Wu, Y. (2026). Efficacy and safety of tumour necrosis factor inhibitors in unexplained recurrent spontaneous abortion: A systematic review and meta-analysis. Journal of Reproductive Immunology. https://doi.org/10.1016/j.jri.2026.104956

Vancouver

Gu X, Zhou C, Qiu H, Bao Y, He Y, Zhu J, et al. Efficacy and safety of tumour necrosis factor inhibitors in unexplained recurrent spontaneous abortion: A systematic review and meta-analysis. Journal of Reproductive Immunology. 2026. doi:10.1016/j.jri.2026.104956

BibTeX
@article{Gu2026,
  author = {Gu, Xuan and Zhou, Chao and Qiu, Hexiang and Bao, Yifan and He, Yuanyuan and Zhu, Jing and Yue, Jun and Wang, Yan and Man, Yicun and Zhuang, Yue and Yang, Yong and Wu, Yue},
  title = {Efficacy and safety of tumour necrosis factor inhibitors in unexplained recurrent spontaneous abortion: A systematic review and meta-analysis},
  journal = {Journal of Reproductive Immunology},
  year = {2026},
  doi = {10.1016/j.jri.2026.104956}
}
Kostenlos starten →